They're all talking about HPV, or human papillomavirus. It's the most common sexually transmitted infection, but it's also ...

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

Merck (MRK) is a leading global healthcare company recognized for its groundbreaking pharmaceutical products and vaccines.

Financial writer advises caution on investing in Merck & Co., Inc. due to negative sentiment and potential price declines. Click for more on MRK Q4 earnings.

As the Q4 2024 pharma earnings period rolls on through the first month of President Donald Trump’s second term, executives ...

Artificial intelligence could be used to prescribe medications to patients — if a new bill makes its way through Congress ...

Cancer researchers are one step closer to developing an effective vaccine to treat people with clear cell renal cell ...

Last week’s full-year results from GlaxoSmithKline (GSK) do not answer every concern the sceptics may have regarding current ...

4Q23 results included charges related to the Daiichi Sankyo collaboration .

Moderna and Merck & Co have expanded their partnership to develop and commercialise novel personalised messenger RNA (mRNA) cancer vaccines. This expansion of their 2016 collaboration will ...